GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/IBD/Ultraprocessed Grains Increase IBD Risk: AJG | June 2026

Ultraprocessed Grains Increase IBD Risk: AJG | June 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated June 1, 2026

Quick Answer

• This large prospective PURE study evaluated the relationship between ultraprocessed grain consumption and the future development of inflammatory bowel disease across 124,590 participants from 21 countries. • Ultraprocessed grains include heavily refined grain products that often contain additives, emulsifiers, preservatives, flavour enhancers, and other industrial ingredients.


  • This large prospective PURE study evaluated the relationship between ultraprocessed grain consumption and the future development of inflammatory bowel disease across 124,590 participants from 21 countries.
  • Ultraprocessed grains include heavily refined grain products that often contain additives, emulsifiers, preservatives, flavour enhancers, and other industrial ingredients.
  • Higher consumption of ultraprocessed grains was associated with a significantly increased risk of developing IBD.
  • Individuals consuming ≥19 g/day of ultraprocessed grains had nearly double the risk of IBD compared with those consuming less than 9 g/day.
  • The association remained significant after adjustment for major confounders, including age, sex, smoking, dietary habits, and physical activity.
  • The findings support growing evidence linking Westernised dietary patterns and food processing to intestinal inflammation.
  • In contrast, consumption of fresh bread and rice was associated with a lower risk of developing IBD.
  • The study also confirmed a broader dietary signal: higher overall intake of ultraprocessed foods was strongly associated with future IBD development.
  • Participants consuming five or more servings of ultraprocessed foods daily had almost a fourfold higher risk of IBD compared with those consuming less than one serving per day.
  • Several biological mechanisms may explain the findings, including:

Alteration of gut microbiota

Increased intestinal permeability

Disruption of the mucus barrier

Exposure to food additives and emulsifiers

Enhanced mucosal immune activation

  • The study adds further support to the hypothesis that environmental and dietary factors contribute substantially to the rising global incidence of IBD.
  • Although observational, the prospective design and multinational nature of the PURE cohort strengthen the validity of the findings.
  • The study cannot identify which specific component of ultraprocessed grains is responsible for the increased risk, and further mechanistic research is needed.
  • From a clinical perspective, dietary counselling aimed at reducing ultraprocessed food consumption may become an increasingly important component of IBD prevention strategies.

Bottom line: Higher consumption of ultraprocessed grains is associated with a significantly increased risk of developing IBD, while less processed staple foods, such as fresh bread and rice, appear to be associated with lower risk. The findings reinforce the importance of minimising ultraprocessed foods as part of a gut-healthy dietary pattern

Related Q&A

IBD Across Ethnicities: Gastroenterology | July 2026

Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...

Moving Beyond the "Wait to Fail" Strategy in ASUC: FG | 2026

Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...

FMT in Ulcerative Colitis: JGH | July 2026

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...

Engineering Immune Cell Therapies for IBD: Nat Re Gastroe & Hepato | June 2026

Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...

Real-World IBD Patients Rarely Meet Clinical Trial Criteria: AJG | June 2026

Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...

Mirikizumab in Ulcerative Colitis: JCC | June 2026

Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer